PDF herunterladen
Aktuelle Neurologie 2003; 30(2): 51-58
DOI: 10.1055/s-2003-37568
Neues in der Neurologie
© Georg Thieme Verlag Stuttgart · New York

Morbus Parkinson und Neuroprotektion: Traum oder Realität?

Parkinson's Disease and Neuroprotection: Dream or Reality?J.  Schwarz1 , H.  Reichmann2
  • 1Klinik und Poliklinik für Neurologie, Universität Leipzig
  • 2Klinik und Poliklinik für Neurologie, Technische Universität Dresden
Wir danken Frau Ulrike Tetzlaff für ihre Hilfe bei der Erstellung des Manuskriptes
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. März 2003 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Neuroprotektive Therapiestrategien des Morbus Parkinson werden seit vielen Jahren in den verschiedenen In-vitro- und In-vivo-Modellen mit Erfolg untersucht. Leider konnten diese Ergebnisse bisher nicht in die Klinik übertragen werden. Dies ist zumindest partiell auf das Fehlen eines Tiermodells mit spezifischer chronischer Degeneration der dopaminergen Neurone zurückzuführen. Dennoch konnten nun Ergebnisse vorgelegt werden, die nahe legen, dass der Verlauf dieser Erkrankung unter der Therapie mit Dopaminagonisten günstiger verläuft als unter der Behandlung mit L-DOPA. Gemessen wurde die Progredienz der Erkrankung mit der Darstellung der FDOPA-Aufnahme oder der Dopamintransporterbindung mittels nuklearmedizinischer Verfahren. Ob es sich hierbei um eine echte Neuroprotektion handelt, kann in Ermangelung der Kenntnis des natürlichen Verlaufs noch nicht beurteilt werden. Diese Studien geben zumindest Anlass zu der Hoffnung, dass in der nahen Zukunft auch der Nachweis der Neuroprotektion gelingen wird.

Abstract

Neuroprotection has been successfully applied using various in vitro and in vivo models for Parkinson's disease. Unfortunately, the translation of such positive results into clinical practice has not been possible. We believe that one of the main issues is the lack of an appropriate animal model with specific chronic progressive degeneration of dopaminergic neurons. However, recent clinical trials comparing the progression of the functional decline of dopaminergic neurons under treatment with a dopamine agonist compared with L-DOPA indicated that the degeneration of dopaminergic neurons is less pronounced when patients are treated with a dopamine agonist. The function of dopaminergic neurons was assessed using quantification of either FDOPA uptake or dopamine transporter binding. Whether dopamine agonists exert a true neuroprotective effect remains unknown as long as comparable data on the natural course are pending. There is considerable hope that neuroprotection will be proven in upcoming clinical trials.

Literatur

  • 1 Rajput A H, Offord K P, Beard C M. et al . Epidemiology of parkinsonism: incidence, classification, and mortality.  Ann Neurol. 1984;  16 278-282
    CrossrefPubMedGoogle Scholar
  • 2 Schoenberg B S, Anderson D W, Haerer A F. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi.  Neurology. 1985;  35 841-845
    PubMedGoogle Scholar
  • 3 Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.  Ann Neurol. 1992;  32 804-812
    CrossrefPubMedGoogle Scholar
  • 4 Gerlach M, Double K, Riederer P. et al . Iron in the Parkinsonian substantia nigra.  Mov Disord. 1997;  12 258-260
    PubMedGoogle Scholar
  • 5 Berman S B, Hastings T G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease.  J Neurochem. 1999;  73 1127-1137
    CrossrefPubMedGoogle Scholar
  • 6 Schapira A H. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia.  Biochim Biophys Acta. 1999;  1410 159-170
    PubMedGoogle Scholar
  • 7 Janetzky B, Hauck S, Youdim M B. et al . Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease.  Neurosci Lett. 1994;  169 126-128
    CrossrefPubMedGoogle Scholar
  • 8 Reichmann H, Naumann M, Hauck S. et al . Respiratory chain and mitochondrial deoxyribonucleic acid in blood cells from patients with focal and generalized dystonia.  Mov Disord. 1994;  9 597-600
    CrossrefPubMedGoogle Scholar
  • 9 Vajda F J. Neuroprotection and neurodegenerative disease.  J Clin Neurosci. 2002;  9 4-8
    CrossrefPubMedGoogle Scholar
  • 10 Spencer P S, Roy D N, Ludolph A. et al . Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA.  Lancet. 1986;  2 1066-1067
    PubMedGoogle Scholar
  • 11 Ludolph A C, Spencer P S. Toxic models of upper motor neuron disease.  J Neurol Sci. 1996;  139, Suppl 53-59
    CrossrefPubMedGoogle Scholar
  • 12 Labarca L, Schwarz J, Deshpande P. et al . Point mutant mice with hypersensitive a4 nicotinic receptors show dopaminergic deficits and increased anxiety.  Proc Natl Acad Sci USA. 2001;  98 2786-2791
    CrossrefPubMedGoogle Scholar
  • 13 Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.  J Neural Transm. 1996;  103 987-1041
    CrossrefPubMedGoogle Scholar
  • 14 Vizuete M L, Merino M, Cano J. et al . In vivo protection of striatal dopaminergic system against 1-methyl-4-phenylpyridinium neurotoxicity by phenobarbital.  J Neurosci Res. 1997;  49 301-308
    CrossrefPubMedGoogle Scholar
  • 15 Zou L, Jankovic J, Rowe D B. et al . Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity.  Life Sci. 1999;  64 1275-1285
    CrossrefPubMedGoogle Scholar
  • 16 Schapira A H. Neuroprotection and dopamine agonists.  Neurology. 2002;  58 S9-S18
    PubMedGoogle Scholar
  • 17 Felten D L, Felten S Y, Fuller R W. et al . Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats.  Neurobiol Aging. 1992;  13 339-351
    CrossrefPubMedGoogle Scholar
  • 18 Schulz J B, Matthews R T, Muqit M M. et al . Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.  J Neurochem. 1995;  64 936-939
    PubMedGoogle Scholar
  • 19 Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A. et al . Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease.  J Neurochem. 2000;  74 1605-1612
    CrossrefPubMedGoogle Scholar
  • 20 Beal M F. Coenzyme Q10 as a possible treatment for neurodegenerative diseases.  Free Radic Res. 2002;  36 455-460
    CrossrefPubMedGoogle Scholar
  • 21 Storch A, Ludolph A C, Schwarz J. HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism.  Neurochem Int. 1999;  35 393-403
    CrossrefPubMedGoogle Scholar
  • 22 Matthews R T, Ferrante R J, Klivenyi P. et al . Creatine and cyclocreatine attenuate MPTP neurotoxicity.  Exp Neurol. 1999;  157 142-149
    CrossrefPubMedGoogle Scholar
  • 23 Obinu M C, Reibaud M, Blanchard V. et al . Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.  Mov Disord. 2002;  17 13-19
    CrossrefPubMedGoogle Scholar
  • 24 Benazzouz A, Boraud T, Dubedat P. et al . Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.  Eur J Pharmacol. 1995;  284 299-307
    CrossrefPubMedGoogle Scholar
  • 25 Boireau A, Dubedat P, Bordier F. et al . Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.  Neuroreport. 1994;  5 2657-2660
    PubMedGoogle Scholar
  • 26 Turski L, Bressler K, Rettig K J. et al . Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.  Nature. 1991;  349 414-418
    CrossrefPubMedGoogle Scholar
  • 27 Steece-Collier K, Chambers L K, Jaw-Tsai S S. et al . Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.  Exp Neurol. 2000;  163 239-243
    CrossrefPubMedGoogle Scholar
  • 28 Fredriksson A, Gentsch C, Archer T. Effect of the competitive NMDA antagonist, CGP 40 116, and a low dose of l-Dopa on the motor activity deficit of MPTP-treated mice.  Behav Pharmacol. 1994;  5 599-606
    PubMedGoogle Scholar
  • 29 Pidoplichko V, DeBiasi M, Williams J. et al . Nicotine activates and desensitizes midbrain dopamine neurons.  Nature. 1997;  390 401-404
    CrossrefPubMedGoogle Scholar
  • 30 Grenhoff J, Janson A M, Svensson T H. et al . Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitransected at the meso-diencephalic junction.  Brain Res. 1991;  562 347-351
    CrossrefPubMedGoogle Scholar
  • 31 Janson A, Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat.  Neuroscience. 1993;  57 931-941
    CrossrefPubMedGoogle Scholar
  • 32 Fenster C P, Whitworth T L, Sheffield E B. et al . Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine.  J Neurosci. 1999;  19 4804-4814
    PubMedGoogle Scholar
  • 33 Balfour D J. Neural mechanisms underlying nicotine dependence.  Addiction. 1994;  89 1419-1423
    PubMedGoogle Scholar
  • 34 Futami T, Takakusaki K, Kitai S T. Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta.  Neurosci Res. 1995;  21 331-342
    CrossrefPubMedGoogle Scholar
  • 35 Piallat B, Benazzouz A, Benabid A L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies.  Eur J Neurosci. 1996;  8 1408-1414
    PubMedGoogle Scholar
  • 36 Takada M, Matsumura M, Kojima J. et al . Protection against dopaminergic nigrostriatal cell death by excitatory input ablation.  Eur J Neurosci. 2000;  12 1771-1780
    CrossrefPubMedGoogle Scholar
  • 37 Zazpe A, Del Rio J. Neurotrophins. II: therapeutic potential.  Rev Med Univ Navarra. 1997;  41 180-184
    PubMedGoogle Scholar
  • 38 Bradford H F, Zhou J, Pliego-Rivero B. et al . Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease.  Adv Neurol. 1999;  80 19-25
    PubMedGoogle Scholar
  • 39 Kordower J H, Emborg M E, Bloch J. et al . Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.  Science. 2000;  290 767-773
    CrossrefPubMedGoogle Scholar
  • 40 Grondin R, Zhang Z, Yi A. et al . Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.  Brain. 2002;  125 2191-2201
    CrossrefPubMedGoogle Scholar
  • 41 Kragten E, Lalande I, Zimmermann K. et al . Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl.  J Biol Chem. 1998;  273 5821-5828
    CrossrefPubMedGoogle Scholar
  • 42 Carvey P M, Pieri S, Ling Z D. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.  J Neural Transm. 1997;  104 209-228
    CrossrefPubMedGoogle Scholar
  • 43 Sheng G, Zhang J, Pu X. et al . Protective effect of verbascoside on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in PC12 cells.  Eur J Pharmacol. 2002;  451 119
    CrossrefPubMedGoogle Scholar
  • 44 Kofuji P, Hofer M, Millen K J. et al . Functional analysis of the mutant weaver GIRK2 potassium channel and rescue of weaver granule cells.  Neuron. 1996;  16 941-952
    CrossrefPubMedGoogle Scholar
  • 45 Nadeau H, McKinney S, Anderson D J. et al . ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons.  J Neurophysiol. 2000;  84 1062-1075
    PubMedGoogle Scholar
  • 46 Snyder S H, Sabatini D M, Lai M M. et al . Neural actions of immunophilin ligands.  Trends Pharmacol Sci. 1998;  19 21-26
    CrossrefPubMedGoogle Scholar
  • 47 Hirsch E C, Hunot S, Damier P. et al . Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?.  Ann Neurol. 1998;  44 S115-120
    PubMedGoogle Scholar
  • 48 Parkinson-Study-Group . Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group.  N Engl J Med. 1989;  321 1364-1371
    PubMedGoogle Scholar
  • 49 Parkinson-Study-Group . Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group.  N Engl J Med. 1993;  328 176-183
    CrossrefPubMedGoogle Scholar
  • 50 Uitti R J, Rajput A H, Ahlskog J E. et al . Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.  Neurology. 1996;  46 1551-1556
    PubMedGoogle Scholar
  • 51 Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.  N Engl J Med. 1994;  330 585-591
    CrossrefPubMedGoogle Scholar
  • 52 Hellenbrand W, Seidler A, Robra B P. et al . Smoking and Parkinson's disease: a case-control study in Germany.  Int J Epidemiol. 1997;  26 328-339
    CrossrefPubMedGoogle Scholar
  • 53 Gorell J M, Rybicki B A, Johnson C C. et al . Smoking and Parkinson's disease: a dose-response relationship (see comments).  Neurology. 1999;  52 115-119
    PubMedGoogle Scholar
  • 54 Kelton M C, Kahn H J, Conrath C L. et al . The effects of nicotine on Parkinson's disease.  Brain Cogn. 2000;  43 274-282
    PubMedGoogle Scholar
  • 55 Tanner C M, Goldman S M, Aston D A. et al . Smoking and Parkinson's disease in twins.  Neurology. 2002;  58 581-588
    PubMedGoogle Scholar
  • 56 Patel N K, Heywood P, Hotton G R. et al . Chronic intraputaminal infusion of glial derived neurotrophic factor (GDNF) in the treatment of advanced Parkinson's disease.  Mov Disord. 2002;  17, Suppl 5 S100
    PubMedGoogle Scholar
  • 57 Whone A L, Remy P, Davis M R. et al . The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-DOPA.  Neurology. 2002;  58, Suppl A82-A83
    PubMedGoogle Scholar
  • 58 Marek K, Seibyl J, Shoulson I. et al . Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.  JAMA. 2002;  287 1653-1661
    CrossrefPubMedGoogle Scholar
  • 59 Oertel W H, Schwarz J, Leenders K L. et al . Results of a 3-year randomized, double-blind, PET-controlled study of pergolide vs L-dopa as monotherapy in early Parkinson's Disease (PELMOPET-trial).  J Neurol Sci. 2001;  187, Suppl S444
    PubMedGoogle Scholar
  • 60 Guttman M, Stewart D, Hussey D. et al . Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.  Neurology. 2001;  56 1559-1564
    PubMedGoogle Scholar
  • 61 Nurmi E, Bergman J, Eskola O. et al . Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.  J Cereb Blood Flow Metab. 2000;  20 1604-1609
    PubMedGoogle Scholar
  • 62 Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.  Arch Neurol. 1999;  56 529-535
    CrossrefPubMedGoogle Scholar
  • 63 Shults C W, Oakes D, Kieburtz K. et al . Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.  Arch Neurol. 2002;  59 1541-1550
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Johannes Schwarz

Klinik und Poliklinik für Neurologie · Universität Leipzig

Liebigstraße 22 a

04103 Leipzig

eMail: tetu@medizin.uni-leipzig.de

      >